Neoadjuvant sacituzumab tirumotecan with or without osimertinib for resectable EGFR‑mutated non‑small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open‑label, multicenter Phase 2 study testing sacituzumab tirumotecan either alone or combined with the EGFR inhibitor osimertinib as preoperative (neoadjuvant) therapy in patients with resectable EGFR‑mutated non‑small cell lung cancer. Participants who meet eligibility will be assigned to one of the treatment arms and receive study drugs prior to planned surgical resection. The trial will monitor safety, tolerability, and measures of anti‑tumor activity such as tumor shrinkage and pathological response at surgery. Outcomes will inform whether this combination or monotherapy can improve surgical outcomes and short‑term disease control in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female, ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF).
2. Histologically or cytologically confirmed NSCLC.
3. No prior systemic anti-tumor therapy.
4. No prior local therapy for NSCLC.
5. Confirmed by tumor histology, or cytology to have EGFR sensitizing mutations.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
7. At least one target lesion as assessed by the investigator according to RECIST v1.1.
8. Life expectancy ≥ 24 weeks.
9. Adequate organ and bone marrow function.
10. For female participants of childbearing potential and male participants with partners of childbearing potential, they must agree to use effective medical contraception from the start of signing the ICF until 6 months after the last dose.
11. Participants must voluntarily join this study, sign the ICF, and be able to comply with the protocol-specified visits and related procedures.

Exclusion Criteria:

1. Tumor histology or cytology confirming combined small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma or squamous cell carcinoma components of more than 10%.
2. Participants with other malignant tumors within 3 years prior to randomization.
3. Resting electrocardiogram (ECG) showing clinically significant abnormal results.
4. Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
5. Uncontrolled systemic diseases in the investigator's judgment.
6. History of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis, have current ILD or non-infectious pneumonitis.
7. Clinically severe lung damage due to complications of lung disorder.
8. Participants who have received systemic corticosteroids therapy with \> 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before randomization.
9. Known active pulmonary tuberculosis.
10. Known history of allogeneic organ transplant and allogeneic hematopoietic stem cell transplant.
11. Active hepatitis B.
12. Positive for human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
13. Known hypersensitivity to osimertinib, sacituzumab tirumotecan, or any of their components (including but not limited to polysorbate-20); known history of severe hypersensitivity to other biologics.
14. Have received a live vaccine within 30 days prior to randomization, or plan to receive a live vaccine during the study.
15. Pregnant or lactating women.
16. Any condition that, in the investigator's opinion, would interfere with the evaluation of the study drug, participant safety, or interpretation of study results, or any other condition that the investigator considers unsuitable for participation in this study.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yina Diao
• Email: diaoyina@kelun.com
• Phone: 028-67252634

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Osimertinib plus sacituzumab tirumotecan for EGFR-mutant advanced non-small cell lung cancer with persistent ctDNA after initial osimertinib

  This trial will test whether adding sacituzumab tirumotecan to osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer whose blood ctDNA remains positive after one cycle of osimertinib.

  Recruiting at 4 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 3 other locations · NCT07375316

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options

  This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.

  Recruiting at 10 sites Phase 3 Bristol-Myers Squibb · Beverly Hills, California and 204 other locations · NCT07680790

• BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC

  A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting at 2 sites Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07642024

• Barriers and facilitators to sticking with osimertinib after early-stage NSCLC

  This study asks how adults with early-stage NSCLC in China continue or stop adjuvant osimertinib, by talking with patients and doctors to understand what helps or hinders persistence.

  Recruiting AstraZeneca · Beijing · NCT07542210

• Ivonescimab with datopotamab deruxtecan or osimertinib for EGFR‑mutant non‑small cell lung cancer

  This trial will test whether combining ivonescimab with datopotamab deruxtecan or with osimertinib is safe and helps people with metastatic EGFR‑mutant non‑small cell lung cancer who have already received third‑generation EGFR inhibitors and chemotherapy.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.